Business Context and Reporting Period
This Form 8-K, filed on March 28, 2023, by Oscar Health, Inc. (OSCR), reports a significant executive leadership transition effective April 3, 2023. Mark T. Bertolini is appointed as Chief Executive Officer and Board member, while co-founder Mario Schlosser transitions to President of Technology. The filing details employment agreements, equity compensation, and the cancellation of founder awards.
Key Financial Metrics and Compensation
The filing does not report operational financial metrics such as revenue, profit, or cash flow for a specific period. However, it discloses specific financial terms related to executive compensation and accounting charges:
- CEO Base Salary: $600,000 annually.
- CEO Target Bonus: 30% of base salary.
- CEO Equity Grant: 10,320,000 shares of Class A common stock (2,866,666 RSUs and 7,453,334 PSUs).
- Accounting Charge: Approximately $46,000,000 non-cash stock compensation charge expected in Q1 2023 due to the cancellation of founder awards.
Material Changes Versus Prior Period
The primary material change is the departure of Mario Schlosser from the CEO role and the appointment of Mark T. Bertolini. Additionally, the Company's founders (Schlosser and Joshua Kushner) cancelled performance-based stock awards covering a total of 6,344,779 shares to mitigate dilution from the new CEO's sign-on package. The Board also amended the 2022 Employee Inducement Incentive Award Plan, increasing authorized shares from 5,000,000 to 18,320,000.
Guidance, Outlook, and Risks
Guidance: The Company reaffirmed its full-year 2023 guidance as originally issued on February 9, 2023. Management stated the $46 million non-cash charge from the founder award cancellations is not expected to impact key metrics or full-year guidance.
Outlook: The transition aims to leverage Mr. Bertolini's extensive healthcare and executive experience to drive innovation and expansion.
Risks: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks outlined in the 2022 Form 10-K. Specific risks include the uncertainty of achieving the performance goals tied to Mr. Bertolini's equity awards.
Investor Verification Checklist
- Verify the impact of the $46 million non-cash charge on Q1 2023 earnings per share (EPS) and net income.
- Review the specific performance metrics (Price Per Share Goals) required for Mr. Bertolini's 7.45 million PSUs to vest.
- Confirm the details of the "at-will" employment terms and severance provisions for both Mr. Bertolini and Mr. Schlosser.
- Monitor the dilution effect of the 10.32 million shares granted to Mr. Bertolini versus the 6.34 million shares cancelled by founders.
- Check the updated share count available under the amended 2022 Inducement Plan (18,320,000 shares).